Acumen Pharmaceuticals Analyst Ratings
Acumen Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 07/20/2023 | 100% | B of A Securities | → $14 | Reinstates | → Buy |
| 07/17/2023 | 85.71% | Cantor Fitzgerald | → $13 | Reiterates | Overweight → Overweight |
| 07/17/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/18/2023 | 85.71% | Cantor Fitzgerald | → $13 | Initiates Coverage On | → Overweight |
| 03/28/2023 | 85.71% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 03/28/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 02/02/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 11/15/2022 | 128.57% | Credit Suisse | $17 → $16 | Maintains | Outperform |
| 10/05/2022 | 214.29% | BTIG | $15 → $22 | Maintains | Buy |
| 07/15/2022 | 114.29% | BTIG | → $15 | Initiates Coverage On | → Buy |
| 06/30/2022 | 114.29% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 03/29/2022 | 142.86% | Credit Suisse | $26 → $17 | Maintains | Outperform |
| 01/21/2022 | 100% | B of A Securities | $16 → $14 | Upgrades | Neutral → Buy |
| 07/26/2021 | 285.71% | UBS | → $27 | Initiates Coverage On | → Buy |
| 07/26/2021 | 185.71% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
| 07/26/2021 | 271.43% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 07/26/2021 | 285.71% | Stifel | → $27 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 07/20/2023 | 100% | B of A證券 | →$14 | 恢復 | →購買 |
| 07/17/2023 | 85.71% | 康託·菲茨傑拉德 | →$13 | 重申 | 超重→超重 |
| 07/17/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | 購買→購買 |
| 2023年05月18日 | 85.71% | 康託·菲茨傑拉德 | →$13 | 開始承保 | →超重 |
| 03/28/2023 | 85.71% | 瑞士信貸 | $16→$13 | 維護 | 跑贏大盤 |
| 03/28/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | →購買 |
| 02/02/2023 | 114.29% | HC Wainwright公司 | →$15 | 重申 | →購買 |
| 2022年11月15日 | 128.57% | 瑞士信貸 | $17→$16 | 維護 | 跑贏大盤 |
| 10/05/2022 | 214.29% | BTIG | $15→$22 | 維護 | 買 |
| 07/15/2022 | 114.29% | BTIG | →$15 | 開始承保 | →購買 |
| 2022/06/30 | 114.29% | HC Wainwright公司 | →$15 | 開始承保 | →購買 |
| 03/29/2022 | 142.86% | 瑞士信貸 | $26→$17 | 維護 | 跑贏大盤 |
| 2022年01月21日 | 100% | B of A證券 | $16→$14 | 升級 | 中性→購買 |
| 07/26/2021 | 285.71% | 瑞銀集團 | →$27 | 開始承保 | →購買 |
| 07/26/2021 | 185.71% | B of A證券 | →$20 | 開始承保 | →中性 |
| 07/26/2021 | 271.43% | 瑞士信貸 | →$26 | 開始承保 | →跑贏大盤 |
| 07/26/2021 | 285.71% | Stifel | →$27 | 開始承保 | →購買 |
What is the target price for Acumen Pharmaceuticals (ABOS)?
Acumen PharmPharmticals(ABOS)的目標價是多少？
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $15.00 expecting ABOS to rise to within 12 months (a possible 114.29% upside). 10 analyst firms have reported ratings in the last year.
慧聰製藥(納斯達克代碼：ABOS)的最新目標價是由HC Wainwright&Co.於2023年8月9日報道的。這家分析公司將目標價定為15美元，預計ABOS將在12個月內上漲至(可能上漲114.29%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
Acumen PharmPharmticals(ABOS)的最新分析師評級是多少？
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ: ABOS) was provided by HC Wainwright & Co., and Acumen Pharmaceuticals reiterated their buy rating.
分析師對Acumen PharmPharmticals(納斯達克代碼：ABOS)的最新評級由HC Wainwright&Co.提供，Acumen製藥公司重申其買入評級。
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Acumen PharmPharmticals(ABOS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Acumen製藥的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Acumen製藥的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右提供。
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
分析師對Acumen PharmPharmticals(ABOS)的評級正確嗎？
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a reiterated with a price target of $0.00 to $15.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $7.00, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Acumen PharmPharmticals(ABOS)評級被重申，目標價在0.00美元至15.00美元之間。Acumen PharmPharmticals(ABOS)目前的交易價格為7.00美元，在分析師的預測範圍內。